LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--May 23, 2006--BioSante Pharmaceuticals, Inc. (Amex: BPA - News) today announced that Dr. Steve Bell, vice president of research and pre-clinical development, presented a case study highlighting the potential of BioVant(TM), the Company's calcium phosphate (CaP) nanoparticle-based vaccine adjuvant, in influenza virus vaccines, including H5N1 avian influenza, or bird flu. The presentation took place today at 9 a.m. ET today at the Vaccine Discovery and Commercialization Conference in Philadelphia.
